New Website Coming! As part of our merger with St. Paul Research, we’re creating a new website that will house all of our collective content under one roof, bringing you a higher level of research and service through their analysts’ additional insight, expertise, and perspective. Be on the lookout for more information in advance of our new website launch on Tuesday, May 18.

New Cancer Treatment Weapon

Aaron Gentzler“As a young man, I left home, moving to a significantly lower-tax area. I did so after I ran the numbers on how the effective tax rate hurt wealth accumulation, especially when combined with other federal taxes. (At the time, combined federal and state taxes eliminated about 30% of my income.)

“Best decision I could have made. Lower taxes made a tremendous difference.”

Here’s the twist: “I’ll leave the U.S. (permanently) and surrender my citizenship if the feds tax me to the extent they’re discussing. If taxes increase that much, then I hope MANY Americans of all income levels vote with their feet by leaving too.”

We actually have a number of expat readers; if you’re one of them, write in with reasons why you left for a life abroad. How’s life been since?

Send your opinions to, TheRundownFeedback@SevenFigurePublishing.com.

Your Rundown for Friday, April 30, 2021…

New Weapon In Cancer Treatment

“More than a century ago, physicians noticed that cancer patients sometimes had tumors recede after an infection,” says our science and technology specialist Ray Blanco. “Sometimes even a generalized infection causing a high fever had an effect.

“This led to some of the early research in what we today call cancer immunotherapy,” he says. “But other areas of therapeutic cancer research advanced faster, so cancer immunotherapy largely took a back seat to surgery, chemotherapy and radiation therapy.

“It’s taken decades of intense research,” Ray continues, “but in the past few years, we’ve seen the first of these cancer therapies approved where the goal is to help the patient’s own body heal itself, rather than attack the cancer directly via toxic drugs or ionizing radiation.

“These new wonder therapies aren’t without drawbacks, however,” says Ray. “They can be incredibly expensive.

“FDA-approved cell-based immunotherapies require each batch to be made specifically to the patient, using the patient’s own cells. This requires not just a blood extraction to harvest the patient’s T cells but also extensive lab work to modify and expand the number of cells prior to re-infusing them back into the patient.

“Moreover, these therapies are generally reserved as a last line because they can be dangerous. Hyperactivated T cells ravaging a patient’s cancer sound good in theory, but in practice, they can lead to deadly cytokine release syndrome where the patient’s own immune response can be so strong it kills them.

“Fortunately, biotechnologists are working on newer, cheaper, safer immunotherapies,” Ray says. “As they make their way through development and get to market, they will help save thousands of lives and earn fortunes for their developers and investors.”

We’ll follow up on some biotech companies at the forefront of cancer immunotherapy research…

Market Rundown for Friday, April 30, 2021

S&P 500 futures are down 23 points to 4,180.

Oil is down 2.15% to $63.61 for a barrel of West Texas Intermediate.

Gold is up $1.50 to $1,769.70 per ounce.

Bitcoin is up 4.3% to $55,233.50.

Send your comments and questions to, TheRundownFeedback@SevenFigurePublishing.com.

Have an outstanding weekend! Check back Monday…

For the Rundown,

Aaron Gentzler

Aaron Gentzler

You May Also Be Interested In:

Aaron Gentzler

Aaron Gentzler is the publisher of Seven Figure Publishing. He is also the editor of The Rundown and has been with Agora Financial / Seven Figure Publishing since 2005. He's been covering technology and markets for over a decade.

View More By Aaron Gentzler